MYOCARDITIS FOLLOWING mRNA COVID VACCINE COMPARED TO PAEDIATRIC MULTISYSTEM INFLAMMATORY SYNDROME MULTICENTER RETROSPECTIVE STUDY
Y. Butbul1, K. Kaidar2, P. J. Hashkes3, Y. Dizitzer2, I. Kanteman1, Y. Berkun4, E. M. Eisenstein4, M. Hamad Saied5, O. Goldzweig6, M. Heshin-Bekenstein7, E. Ling8, M. Feldon9, R. Tal2, G. Amarilyo2, L. Harel2
1Pediatric Rheumatology Service, Ruth Rappaport Children’s Hospital, Rambam Medical Center, Haifa, Israel, Pediatric B, Haifa, Israel
2Schneider Children’s Medical Center, Sackler School of Medicine Tel-Aviv University, Pediatric Rheumatology, Tel Aviv, Israel
3Pediatric Rheumatology Unit, Shaare Zedek Medical Center, Jerusalem, Israel, Pediatric Rheumatology, Jerusalem, Israel
4Department of Pediatrics, Hadassah-Hebrew University Medical Center, Mount Scopus, Jerusalem, Israel, Pediatric rheumatology, Jerusalem, Israel
55Carmel Medical Center, Haifa, Technion–Israel Institute of Technology, Haifa, Pediatric rheumatology, Haifa, Israel
6Kaplan Medical Center, Rehovot, Hebrew University and Hadassa, Jerusalem, Israel, Pediatric Rheumatology, Jerusalem, Israel
7Israel Pediatric Rheumatology Service, Dana Children’s Hospital of Tel Aviv Medical Center, Tel Aviv University, Tel Aviv, Pediatric Rheumatology, Tel Aviv, Israel
8Pediatrics Depatrtment B, Saban Pediatric Medical center for Israel, Soroka University Medical Center, Beer Sheva, Israel, Pediatric B, Beer Sheva, Israel
9Shamir Medical Center, Sackler School of Medicine Tel-Aviv University, Pediatric Rheumatology, Tel Aviv, Israel
Background: Since the development of COVID 19 vaccines, more than 300 million people have been immunized worldwide. Soon after vaccinations were initiated, reports on cases of myocarditis following the second vaccine dose have emerged.
Objectives: This study aims to report our experience with nine patients with post COVID-19 vaccine myocarditis, and to compare them to a cohort of patients who presented with paediatric inflammatory multisystem syndrome (PIMS / PIMS-TS) post COVID 19 infection.
Methods: We collected all reported cases of patients who developed myocarditis following COVID 19 vaccination (Pfizer mRNA BNT162b2), from all pediatric rheumatology centers in Israel, and compared them to the cohort of patients previously diagnosed with PIMS.
Results: Nine patients with myocarditis post-vaccination were identified and compared to 78 patients diagnosed with PIMS. All patients with post-vaccination myocarditis were males who developed symptoms following their second dose of the vaccine. Patients with myocarditis post-vaccination had a shorter duration of stay at the hospital (4.4±1.9 vs. 8.7±4.7 days), less myocardial dysfunction (11.1% vs. 61.5%), and all had excellent outcomes as compared to chronic changes among 9.2% of patients with PIMS.
Conclusion: The clinical course of vaccine-associated myocarditis appears favorable, with resolution of symptoms in all the patients in our cohort. The risk–benefit decision for vaccination remains highly favorable, given the potential morbidity of patients with COVID-19, especially those with PIMS.
Disclosure of Interests: None declared
Citation: , volume 81, supplement 1, year 2022, page 1698
